source
- Merck still sees ‘compelling’ outlook for Terns leukemia drugDespite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.BioPharma Dive · 3mo ago↗ source
- UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyNews of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.BioPharma Dive · 3mo ago↗ source
- Avalyn's upsized IPO; Alector ends another study in GSK partnership🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is selling over 16.5 million shares at $18 apiece. The company is set to start trading as {$AVLN} on the Nasdaq Thursday ...